Lv1
30 积分 2023-11-17 加入
Myeloid-derived suppressor cells (MDSCs) depletion by cabozantinib improves the efficacy of anti-HER2 antibody-based immunotherapy in a 4T1-HER2 murine breast cancer model
15小时前
待确认
Targeting the tumour cell surface in advanced prostate cancer
2天前
已完结
Messenger RNA Vaccines: Beckoning of a New Era in Cancer Immunotherapy
19天前
已完结
Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study
19天前
已完结
Antibody–drug conjugates come of age in oncology
19天前
已完结
Understanding and overcoming resistance to PARP inhibitors in cancer therapy
21天前
已完结
Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study
1个月前
已完结
Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study
1个月前
已完结
Differences in Tumor Microenvironment Dictate T Helper Lineage Polarization and Response to Immune Checkpoint Therapy
1个月前
已完结
Docetaxel suppresses immunotherapy efficacy of natural killer cells toward castration‐resistant prostate cancer cells via altering androgen receptor‐lectin‐like transcript 1 signals
1个月前
已完结
皖公网安备34019202002308
